Alteogen(136,900 +9.35%)Announced on the 25th that it has signed a contract with Merck Germany for the production and supply of human hyaluronidase’ALT-B4′.
The contract was made through Merck’s BioReliance(R) End-to-End Solutions. This solution is a program that helps pharmaceutical and bio companies clinical and commercialization.
Under the agreement, Merck will transfer Alteogen’s existing process to Merck’s cGMP facility in Martiac, France. The facility will provide late CDMO services, including the production of human hyaluronidase to be used in subcutaneous injection (SC) antibody therapy. Merck’s biologics CDMO consists of three facilities in Europe, the United States, and China.
Alteogen explained that the contract secured a global production base for ALT-B4. It is explained that the production of human hyaluronidase in Europe is intended to supply clinical samples and raw materials for commercial production purposes to partnered global pharmaceutical companies.
An Alteogen official said, “We believe that the French facility is suitable for technology transfer and production of ALT-B4, and that strategic interests such as facility use are mutually compatible.” “Through this contract, we can supply products to global markets such as Europe. We have built the foundation.”
He said, “When the first GMP production is completed through European CMO facilities, we plan to receive some staged technical fees (milestone) from a global pharmaceutical company contracted last year.”
Reporter Kim Ye-na [email protected]
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution